Prevention of cardiac allograft vasculopathy with Certican (everolimus): the Stanford University experience within the Certican Phase III clinical trial. (Q45933783)
Jump to navigation
Jump to search
scientific article published in April 2005
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Prevention of cardiac allograft vasculopathy with Certican (everolimus): the Stanford University experience within the Certican Phase III clinical trial. |
scientific article published in April 2005 |
Statements
1 reference
Prevention of cardiac allograft vasculopathy with Certican (everolimus): the Stanford University experience within the Certican Phase III clinical trial. (English)
1 reference
Hannah Valantine
1 reference
1 April 2005
1 reference
24
1 reference
4 Suppl
1 reference
S191-5; discussion S210-1
1 reference